osimertinib
astrazeneca
['osimertinib', 'nsclc', 'sclc']
overall survival improved with osimertinib in resected egfr-mutated nsclc the 5-year overall survival was 85% in the #osimertinib group and 73% in the placebo group (hr, 0.49; 95.03% confidence interval [ci], 0.33 to 0.73; p&lt;0.001) #asco23 
Non-Profit Founder/Leader | ❤️ Doc | Artist Scientist Educator | News Anchor https://t.co/7OIKCgMVAT | RT ≠ endorse | Disclaimer: https://t.co/bwmE2O3U5W